Bio-Rad and Alleghany Health Network partner for patients with solid tumour cancer
Solid tumour cancers account for 90% of adult human cancers and 50% of childhood malignancies
Read More
Tag: AHN Cancer Institute
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
